» Articles » PMID: 35603218

SLAMF Receptor Expression Identifies an Immune Signature That Characterizes Systemic Lupus Erythematosus

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology, linked to alterations in both the innate and the adaptive immune system. Due to the heterogeneity of the clinical presentation, the diagnosis of SLE remains complicated and is often made years after the first symptoms manifest, delaying treatment, and worsening the prognosis. Several studies have shown that signaling lymphocytic activation molecule family (SLAMF) receptors are aberrantly expressed and dysfunctional in SLE immune cells, contributing to the altered cellular function observed in these patients. The aim of this study was to determine whether altered co-/expression of SLAMF receptors on peripheral blood mononuclear cells (PBMC) identifies SLE characteristic cell populations. To this end, single cell mass cytometry and bioinformatic analysis were exploited to compare SLE patients to healthy and autoimmune diseases controls. First, the expression of each SLAMF receptor on all PBMC populations was investigated. We observed that SLAMF1+ B cells (referred to as SLEB1) were increased in SLE compared to controls. Furthermore, the frequency of SLAMF4+ monocytes and SLAMF4+ NK were inversely correlated with disease activity, whereas the frequency SLAMF1+ CD4+ TDEM cells were directly correlated with disease activity. Consensus clustering analysis identified two cell clusters that presented significantly increased frequency in SLE compared to controls: switch memory B cells expressing SLAMF1, SLAMF3, SLAMF5, SLAMF6 (referred to as SLESMB) and circulating T follicular helper cells expressing the same SLAMF receptors (referred to as SLEcTFH). Finally, the robustness of the identified cell populations as biomarkers for SLE was evaluated through ROC curve analysis. The combined measurement of SLEcTFH and SLEB1 or SLESMB cells identified SLE patients in 90% of cases. In conclusion, this study identified an immune signature for SLE based on the expression of SLAMF receptors on PBMC, further highlighting the involvement of SLAMF receptors in the pathogenesis of SLE.

Citing Articles

Mass cytometry: exploring the immune landscape of systemic autoimmune and inflammatory diseases in the past fourteen years.

Kante A, Chevalier M, Sene D, Chauffier J, Mouly S, Chousterman B Front Immunol. 2025; 15:1509782.

PMID: 39896815 PMC: 11782038. DOI: 10.3389/fimmu.2024.1509782.


Proteomic analysis of cardiovascular disease-associated proteins in Korean patients with moderate-to-severe atopic dermatitis.

Jin S, Kim H, Moon J, Kim-Schulze S, Chun Y, Nam H World Allergy Organ J. 2024; 17(8):100949.

PMID: 39220465 PMC: 11363482. DOI: 10.1016/j.waojou.2024.100949.


SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma.

Deng Y, Zhang L, Dai C, Xu Y, Gan Q, Cheng J J Gynecol Oncol. 2024; 35(6):e79.

PMID: 38606823 PMC: 11543254. DOI: 10.3802/jgo.2024.35.e79.


SAP-expressing T peripheral helper cells identify systemic lupus erythematosus patients with lupus nephritis.

Gartshteyn Y, Geraldino-Pardilla L, Khalili L, Bukhari S, Lerrer S, Winchester R Front Immunol. 2024; 15:1327437.

PMID: 38550577 PMC: 10972949. DOI: 10.3389/fimmu.2024.1327437.


Systemic lupus in the era of machine learning medicine.

Zhan K, Buhler K, Chen I, Fritzler M, Choi M Lupus Sci Med. 2024; 11(1).

PMID: 38443092 PMC: 11146397. DOI: 10.1136/lupus-2023-001140.


References
1.
Tsokos G . Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-21. DOI: 10.1056/NEJMra1100359. View

2.
Karampetsou M, Comte D, Suarez-Fueyo A, Katsuyama E, Yoshida N, Kono M . Signaling Lymphocytic Activation Molecule Family Member 1 Engagement Inhibits T Cell-B Cell Interaction and Diminishes Interleukin-6 Production and Plasmablast Differentiation in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2018; 71(1):99-108. PMC: 6310084. DOI: 10.1002/art.40682. View

3.
Kim J, Mathew S, Patel R, Pertusi R, Mathew P . Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin Exp Immunol. 2010; 160(3):348-58. PMC: 2883105. DOI: 10.1111/j.1365-2249.2010.04116.x. View

4.
Ribi C, Trendelenburg M, Gayet-Ageron A, Cohen C, Dayer E, Eisenberger U . The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Med Wkly. 2014; 144:w13990. DOI: 10.4414/smw.2014.13990. View

5.
Spitzer M, Nolan G . Mass Cytometry: Single Cells, Many Features. Cell. 2016; 165(4):780-91. PMC: 4860251. DOI: 10.1016/j.cell.2016.04.019. View